Stock listing
Frankfurt:M8W MediWound Ltd. Aktie
German listing (Frankfurt) of MediWound Ltd. · home listing NASDAQ:MDWD
Follow MediWound Ltd. into a list and get an email when it puts out news.
Share price · FWB:M8W
€12.00 EUR -0.20 (-1.6%)
Close on Nov 20, 2026
- Day range
- €12.00 – €12.00 EURNov 20, 2026
- Market cap
- €154.9M EURAt the close on Nov 20, 2026 · price × 12.91M shares outstanding
- 52-week range
- €10.22 – €17.05 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €4,740 EURMedian day 0 shares · 44 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MDWD · Home | $13.59 USD | -0.02 (-0.1%) | 187,835 | $13.48 | $13.62 | $13.36 | $13.61 | Close on Nov 20, 2026 |
| Frankfurt:M8W | €12.00 EUR | -0.20 (-1.6%) | — | €12.00 | €12.00 | €12.00 | €12.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:M8W · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €12.05 | +0.078 | +0.7% | €11.78 | €12.06 | €11.76 | 0 | |
| €11.97 | -0.356 | -2.9% | €12.37 | €12.49 | €11.82 | 1,600 | |
| €12.33 | +0.529 | +4.5% | €11.73 | €12.39 | €11.54 | 9,600 | |
| €11.80 | +0.201 | +1.7% | €11.80 | €11.90 | €11.79 | 200 | |
| €11.60 | -1.051 | -8.3% | €11.83 | €11.96 | €11.42 | 2,740 | |
| €12.65 | +0.154 | +1.2% | €12.71 | €12.83 | €12.65 | 2,740 | |
| €12.50 | +0.512 | +4.3% | €11.94 | €12.67 | €11.62 | 590 | |
| €11.98 | +1.179 | +10.9% | €11.08 | €12.02 | €11.01 | 2,502 | |
| €10.80 | +0.384 | +3.7% | €10.66 | €10.92 | €10.63 | 0 | |
| €10.42 | -0.20 | -1.9% | €10.42 | €10.42 | €10.42 | 0 | |
| €10.62 | +0.075 | +0.7% | €10.62 | €10.62 | €10.62 | 0 | |
| €10.55 | -0.071 | -0.7% | €10.55 | €10.55 | €10.55 | 0 | |
| €10.62 | -0.081 | -0.8% | €10.60 | €10.62 | €10.55 | 0 | |
| €10.70 | -0.027 | -0.3% | €11.04 | €11.05 | €10.53 | 0 | |
| €10.72 | +0.118 | +1.1% | €10.37 | €10.74 | €10.22 | 0 | |
| €10.61 | +0.243 | +2.3% | €10.61 | €10.61 | €10.61 | 0 | |
| €10.36 | -0.301 | -2.8% | €10.36 | €10.36 | €10.36 | 0 | |
| €10.66 | -0.346 | -3.1% | €10.66 | €10.66 | €10.66 | 0 | |
| €11.01 | +0.037 | +0.3% | €11.01 | €11.01 | €11.01 | 0 | |
| €10.97 | +0.246 | +2.3% | €10.97 | €10.97 | €10.97 | 0 | |
| €10.73 | -0.467 | -4.2% | €10.73 | €10.73 | €10.73 | 216 | |
| €11.19 | -0.198 | -1.7% | €11.19 | €11.19 | €11.19 | 0 | |
| €11.39 | -0.014 | -0.1% | €11.42 | €11.46 | €11.33 | 0 | |
| €11.41 | -0.378 | -3.2% | €11.69 | €11.77 | €11.38 | 0 | |
| €11.78 | -0.095 | -0.8% | €11.78 | €11.78 | €11.78 | 0 | |
| €11.88 | -0.031 | -0.3% | €11.88 | €11.88 | €11.88 | 888 | |
| €11.91 | +0.022 | +0.2% | €11.91 | €11.91 | €11.91 | 0 | |
| €11.89 | -0.088 | -0.7% | €11.89 | €11.89 | €11.89 | 0 | |
| €11.98 | +0.116 | +1.0% | €11.98 | €11.98 | €11.98 | 0 | |
| €11.86 | -0.08 | -0.7% | €11.86 | €11.86 | €11.86 | 0 | |
| €11.94 | +0.064 | +0.5% | €11.94 | €11.94 | €11.94 | 0 | |
| €11.88 | -0.03 | -0.3% | €11.70 | €12.00 | €11.65 | 0 | |
| €11.91 | +0.22 | +1.9% | €12.01 | €12.01 | €11.75 | 78 | |
| €11.69 | +0.252 | +2.2% | €11.37 | €11.72 | €11.31 | 0 | |
| €11.43 | +0.091 | +0.8% | €11.43 | €11.43 | €11.43 | 0 | |
| €11.34 | +0.09 | +0.8% | €11.34 | €11.34 | €11.34 | 0 | |
| €11.25 | -0.195 | -1.7% | €11.25 | €11.25 | €11.25 | 0 | |
| €11.45 | +0.035 | +0.3% | €11.45 | €11.45 | €11.45 | 0 | |
| €11.41 | -0.552 | -4.6% | €11.69 | €11.70 | €11.34 | 0 | |
| €11.97 | +0.397 | +3.4% | €11.15 | €12.02 | €11.08 | 600 | |
| €11.57 | -0.057 | -0.5% | €11.57 | €11.57 | €11.57 | 200 | |
| €11.63 | +0.127 | +1.1% | €11.63 | €11.63 | €11.63 | 0 | |
| €11.50 | +0.347 | +3.1% | €11.35 | €11.55 | €11.33 | 0 | |
| €11.15 | +0.379 | +3.5% | €11.15 | €11.15 | €11.15 | 0 | |
| €10.77 | -0.39 | -3.5% | €10.77 | €10.77 | €10.77 | 0 | |
| €11.16 | +0.216 | +2.0% | €11.16 | €11.16 | €11.16 | 0 | |
| €10.95 | +0.37 | +3.5% | €10.95 | €10.95 | €10.95 | 0 | |
| €10.58 | -0.052 | -0.5% | €10.58 | €10.58 | €10.58 | 0 | |
| €10.63 | -0.118 | -1.1% | €10.63 | €10.63 | €10.63 | 0 | |
| €10.75 | -0.309 | -2.8% | €10.75 | €10.75 | €10.75 | 0 | |
| €11.06 | +0.472 | +4.5% | €11.06 | €11.06 | €11.06 | 0 | |
| €10.58 | -0.364 | -3.3% | €10.58 | €10.58 | €10.58 | 0 | |
| €10.95 | +0.063 | +0.6% | €10.95 | €10.95 | €10.95 | 0 | |
| €10.88 | -0.001 | 0.0% | €10.88 | €10.88 | €10.88 | 0 | |
| €10.89 | -0.151 | -1.4% | €11.07 | €11.13 | €10.73 | 300 | |
| €11.04 | -0.348 | -3.1% | €11.04 | €11.04 | €11.04 | 0 | |
| €11.38 | -0.198 | -1.7% | €11.38 | €11.38 | €11.38 | 0 |
Splits
1 split · FWB:M8W · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-7 | Consolidation |
- Ticker
- Frankfurt:M8W
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026
Latest earnings call · Nov 12, 2026
MediWound (NASDAQ:MDWD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 31 slides
Latest news
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
Nov 5, 2026
Closed €12.05 (+0.7%) on Nov 6, 2026
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
Nov 3, 2026
Closed €12.33 (+4.5%) on Nov 4, 2026
MediWound to Report Third Quarter 2026 Financial Results
Oct 29, 2026
Closed €12.50 (+4.3%) on Oct 29, 2026
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
Sep 22, 2026
Closed €11.69 (+2.2%) on Sep 22, 2026
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
Sep 14, 2026
Closed €11.97 (+3.4%) on Sep 14, 2026
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 2, 2026
Closed €10.58 (-0.5%) on Sep 2, 2026
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 13, 2026
Closed €11.77 (+0.2%) on Aug 13, 2026
MediWound to Report Second Quarter 2026 Financial Results
Jul 29, 2026
Closed €12.69 (+2.4%) on Jul 29, 2026
MediWound Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 170 in all · newest Nov 16, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 12, 2026
- Decks
- 17 decks · latest November 2026
Where MediWound Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MDWD · Home listing | NASDAQ | United States | USD |
| LS Exchange:A110TG | LS Exchange | Germany | EUR |
| Lang & Schwarz:A110TG | Lang & Schwarz | Germany | EUR |
| BOATS:MDWD | BOATS | United States | USD |
| Frankfurt:M8W · This page | Frankfurt | Germany | EUR |
| Stuttgart:M8W | Stuttgart | Germany | EUR |
Cash and shares
Aug 2026 deck · MediWound — Investor Presentation (August 2026)
- Fully diluted
- 16.8 million
Valuation
EV/sales 15.6× against a median of 9.1×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $155.9M USD
- P/E
- Loss
- EV/sales
- 15.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.5×
- Gross margin
- 19.5%
- Operating margin
- −337.8%
- Net margin
- −235.0%
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 0.64
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MediWound Ltd. · NASDAQ:MDWD | US$175.5M | US$155.9M | n/a | 15.6× | n/a | 5.5× | −235.0% | 0.3× | 0.64 |
| Antengene Corporation Limited · HKEX:6996 | US$183.1M | US$107.1M | n/a | 6.8× | n/a | 1.3× | −227.0% | 0.3× | n/a |
| Whitehawk Therapeutics, Inc. · NASDAQ:WHWK | US$181.2M | US$11.70M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.35 |
| Sol-Gel Technologies Ltd. · NASDAQ:SLGL | US$180.6M | US$137.0M | n/a | 95.4× | n/a | 4.2× | n/a | 0.0× | 0.67 |
| Tanvex BioPharma, Inc. · TWSE:6541 | US$180.5M | US$225.7M | n/a | 11.3× | n/a | 1.2× | −222.8% | 0.4× | n/a |
| Korro Bio, Inc. · NASDAQ:KRRO | US$179.4M | US$74.36M | n/a | 57.6× | n/a | 2.0× | n/a | 0.0× | 1.46 |
| Vogenx Inc · NASDAQ:VOGX | US$176.3M | US$94.21M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| Nanexa AB · OMXSTO:NANEXA | US$175.1M | US$170.1M | n/a | 51.4× | n/a | 13.5× | −72.5% | 0.0× | n/a |
| Compugen Ltd. · NASDAQ:CGEN | US$174.3M | US$59.55M | 4.8× | 0.8× | n/a | 2.1× | 47.9% | 0.0× | 1.49 |
| Guangzhou Innogen Pharmaceutical Group Co Ltd Class H · HKEX:2591 | US$170.8M | US$40.22M | n/a | 2.1× | n/a | 1.2× | −259.6% | 0.2× | n/a |
| Entrada Therapeutics, Inc. · NASDAQ:TRDA | US$170.3M | US$24.60M | n/a | 6.2× | n/a | 0.9× | n/a | 0.2× | 1.43 |
| Median of the others | US$177.8M | US$84.29M | 4.8× | 9.1× | 1.7× | −222.8% | 0.0× | 1.43 |
Forecasts
5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 29.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.90 · 2 analysts
- Revenue, year to Dec 2026
- 22.55M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ofer Gonen | Chief Executive Officer |
| Hani Luxenburg | Chief Financial Officer |
| Shmulik Hess | Chief Operating & Commercial Officer |
| Yaron Meyer | EVP, General Counsel & Corporate Secretary |
| Alexandra Teplitsky | VP Quality Assurance |
| Aya Ben Yaakov | VP Clinical & Regulatory Affairs |
| Barry J. Wolfenson | EVP Strategy & Corporate Development |
| Liron Gal | VP Manufacturing Science & Technology |
| Robert J. Snyder | SVP, Global Medical Affairs |
| Ety Klinger | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Nachum Shamir | Chairman |
| David Fox | Board Member |
| Shmuel Rubinstein | Board Member |
| Stephen T. Wills | Board Member |
| Vickie R. Driver | Board Member |
| Yaron Meyer | EVP, General Counsel & Corporate Secretary |
Events
Calls
| Call | When | Status |
|---|---|---|
| MediWound (NASDAQ:MDWD) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q1 2026 Earnings Call | Wed, May 27, 2026 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q3 2025 Earnings Call | Thu, Nov 20, 2025 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q1 2025 Earnings Call | Wed, May 21, 2025 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q4 2024 Earnings Call | Wed, Mar 19, 2025 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q3 2024 Earnings Call | Tue, Nov 26, 2024 · 8:30 AM ET | Replay |
| MediWound (NASDAQ:MDWD) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 8:30 AM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −6.2% |
| Q2 2026 | Aug 13, 2026 · Before open | −2.7% |
| Q1 2026 | May 27, 2026 · Before open | −14.1% |
| Q4 2025 | Mar 5, 2026 · Before open | −0.8% |
| Q3 2025 | Nov 20, 2025 · Before open | −5.6% |
| Q2 2025 | Aug 14, 2025 · Before open | −1.0% |
| Q1 2025 | May 21, 2025 · Before open | −4.7% |
| Q4 2024 | Mar 19, 2025 · Before open | −5.1% |
| Q3 2024 | Nov 26, 2024 · Before open | −2.5% |
| Q2 2024 | Aug 14, 2024 · Before open | −4.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 29, 2024 · Before open | −10.0% |
| Q4 2023 | Mar 21, 2024 · Before open | +2.1% |
| Q3 2023 | Nov 21, 2023 · Before open | −1.9% |
| Q2 2023 | Aug 15, 2023 · After close | −1.5% |
| Q1 2023 | May 30, 2023 · Before open | −7.5% |
| Q4 2022 | Mar 16, 2023 · Before open | −4.6% |
| Q3 2022 | Nov 15, 2022 · Before open | +15.2% |
| Q2 2022 | Aug 9, 2022 · Before open | −1.7% |
| Q1 2022 | May 17, 2022 · Before open | −6.3% |
| Q4 2021 | Mar 17, 2022 · Before open | −0.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 31 slides | November 2026 |
| Investor Presentation (August 2026) | Investor deck | 31 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 31 slides | May 27, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 29 slides | Mar 5, 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | January 2026 |
| Investor Presentation (November 2025) | Investor deck | 29 slides | November 2025 |
| Investor Presentation (August 2025) | Investor deck | 29 slides | August 2025 |
| Investor Presentation (May 2025) | Investor deck | 29 slides | May 2025 |
| Investor Presentation (March 2025) | Investor deck | 30 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 29 slides | January 2025 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2024) | Investor deck | 28 slides | Aug 14, 2024 |
| Technical Presentation (February 2024) | Technical | 12 slides | Feb 12, 2024 |
| Investor Presentation (January 2024) | Investor deck | 29 slides | Jan 8, 2024 |
| Investor Presentation (May 2023) | Investor deck | 22 slides | May 31, 2023 |
| Investor Presentation (January 2023) | Investor deck | 20 slides | Jan 9, 2023 |
| Investor Presentation (July 2022) | Investor deck | 12 slides | Jul 12, 2022 |
| Investor Presentation (June 2015) | Investor deck | 26 slides | Jun 4, 2015 |
Financings
| Raise | Date |
|---|---|
| Bought deal of ordinary shares Closed: US$17.25M raised · US$12.5 a share · H.C. Wainwright & Co., LLC Dealers: H.C. Wainwright & Co., LLC (lead) Use of proceeds: Working capital and general corporate purposes | Nov 5, 2026 |
| Registered direct offering of ordinary shares Closed: US$30M raised · US$17.3 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: a prominent U.S.-based mutual fund Use of proceeds: To advance the company's development programs and commercialization initiatives | Nov 20, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$14.00 a share on Mar 19, 2014.
- Price
- US$14.00 a share
- Shares offered
- 5,000,000 ordinary shares
- Offering size
- US$70 million
- Underwriters' option
- Up to 750,000 more shares
- Listing
- MDWD on the Nasdaq Global Market
- Underwriters
- Credit Suisse, Jefferies, BMO Capital Markets, Oppenheimer & Co. · In the order on the cover
- Shares delivered
- On or about Mar 25, 2014
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 23, 2013 |
| Filed publicly | Feb 10, 2014 |
| Amended 3 times | Newest Mar 14, 2014 |
| Shares registered with an exchange | Mar 12, 2014 |
| Declared effective by the SEC | Mar 19, 2014 |
| Final prospectus, with the price | Mar 21, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 21, 2014 |
| EFFECT · Notice that a registration is effective | Mar 19, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Mar 19, 2014 |
| CORRESP · Letter to the SEC | Mar 17, 2014 |
| F-1/A · Registration statement, amended | Mar 14, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 12, 2014 |
| UPLOAD · Letter from the SEC | Mar 7, 2014 |
| F-1/A · Registration statement, amended | Mar 3, 2014 |
| CORRESP · Letter to the SEC | Feb 18, 2014 |
| F-1/A · Registration statement, amended | Feb 18, 2014 |
All 18 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Feb 12, 2014 |
| F-1 · Registration statement | Feb 10, 2014 |
| CORRESP · Letter to the SEC | Jan 31, 2014 |
| DRS/A · Draft registration statement, amended | Jan 31, 2014 |
| DRS/A · Draft registration statement, amended | Jan 27, 2014 |
| UPLOAD · Letter from the SEC | Jan 16, 2014 |
| DRS/A · Draft registration statement, amended | Jan 15, 2014 |
| DRS · Draft registration statement | Dec 23, 2013 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 21, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.0M | 20.2M | 18.7M | 26.5M | 23.8M | 21.8M | 31.8M | 3.40M | 2.50M | 1.56M |
| Cost of revenue | 13.7M | 17.6M | 15.1M | 13.3M | 15.0M | 14.2M | 11.8M | 2.09M | 1.58M | 2.16M |
| Gross profit | 3.25M | 2.63M | 3.58M | 13.2M | 8.77M | 7.54M | 19.9M | 1.31M | 918.0K | -600.0K |
| Research and development | 14.3M | 8.88M | 7.47M | 10.2M | 10.3M | 7.70M | 4.97M | 4.07M | 5.46M | 7.07M |
| Selling, general and administrative | 8.45M | 8.20M | 6.77M | 6.92M | 6.35M | 5.46M | 5.24M | 3.80M | 3.78M | 4.08M |
| Operating income | -25.3M | -19.4M | -15.3M | -8.35M | -11.2M | -8.84M | 4.49M | -3.96M | -13.7M | -20.2M |
| Depreciation and amortization | 1.86M | 1.48M | 1.30M | 1.27M | 1.24M | 1.09M | 1.15M | 577.0K | 567.0K | 589.0K |
| EBITDA | -23.4M | -17.9M | -14.0M | -7.07M | -9.98M | -7.75M | 5.64M | -3.38M | -13.1M | -19.6M |
| Interest expense | 2.46M | 12.8M | 1.89M | 11.6M | 2.31M | 1.28M | 2.98M | 2.12M | 1.25M | 896.0K |
| Income before tax | -23.7M | -30.2M | -6.53M | -19.5M | -13.5M | -9.28M | 2.07M | -5.67M | -14.5M | -18.9M |
| Income tax | 169.0K | 61.0K | 185.0K | 78.0K | 27.0K | 0 | 0 | -9.69M | 8.46M | -1.27M |
| Net income | -23.9M | -30.2M | -6.72M | -19.6M | -13.6M | -9.20M | 4.96M | -1.06M | -22.1M | -18.9M |
| Earnings per share, basic | -2.10 | -3.03 | -0.75 | -3.93 | -3.48 | -2.38 | 0.18 | -0.04 | -0.82 | -0.86 |
| Earnings per share, diluted | -2.10 | -3.03 | -0.75 | -3.93 | -3.48 | -2.38 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.80M | 9.15M | 11.9M | 33.9M | 11.0M | 17.4M | 7.24M | 6.72M | 36.1M | 28.9M |
| Short-term investments | 48.3M | 34.0M | 29.7M | 0 | 0 | 4.02M | 22.0M | 16.9M | 0 | 1.16M |
| Receivables | 1.62M | 4.80M | 3.70M | 9.33M | 1.78M | 2.77M | 4.11M | 560.0K | 369.0K | 332.0K |
| Inventory | 4.09M | 2.69M | 2.85M | 1.96M | 1.20M | 1.38M | 1.61M | 1.68M | 1.89M | 844.0K |
| Current assets | 60.0M | 52.2M | 49.7M | 45.8M | 15.0M | 26.2M | 35.6M | 32.7M | 41.5M | 33.6M |
| Property, plant and equipment | 18.6M | 14.1M | 9.23M | 2.37M | 2.48M | 2.63M | 2.30M | 2.02M | 1.92M | 1.28M |
| Total assets | 86.3M | 73.5M | 66.5M | 50.0M | 19.7M | 31.1M | 40.6M | 35.3M | 44.1M | 35.8M |
| Accounts payable | 7.65M | 5.28M | 5.53M | 5.66M | 4.69M | 2.99M | 4.07M | 2.71M | 3.25M | 3.32M |
| Current liabilities | 25.7M | 26.5M | 18.1M | 12.1M | 10.7M | 8.27M | 10.4M | 4.90M | 5.43M | 5.38M |
| Long-term debt | 7.38M | 6.84M | ||||||||
| Total debt | 8.15M | 6.93M | 6.35M | 846.0K | 1.39M | 1.74M | 7.49M | |||
| Total liabilities | 42.6M | 42.3M | 34.9M | 39.1M | 24.3M | 23.8M | 25.4M | 26.3M | 34.5M | 28.0M |
| Shareholders' equity | 43.6M | 31.2M | 31.6M | 10.9M | -4.58M | 7.27M | 15.2M | 8.97M | 9.37M | 7.77M |
| Shares outstanding | 12.8M | 10.8M | 9.22M | 7.24M | 3.90M | 27.2M | 27.2M | 27.2M | 27.0M | 21.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -16.1M | -13.6M | -10.5M | -11.9M | -8.92M | -6.89M | 8.29M | -12.2M | -16.5M | -16.4M |
| Capital spending | -5.50M | -6.27M | -6.46M | -555.0K | -489.0K | -923.0K | -792.0K | -522.0K | -1.04M | -671.0K |
| Free cash flow | -21.6M | -19.9M | -16.9M | -12.4M | -9.40M | -7.82M | 7.50M | -12.7M | -17.5M | -17.1M |
| Cash from investing | -17.9M | -8.40M | -34.3M | -481.0K | 3.55M | 17.4M | -6.90M | -17.0M | 437.0K | 1.82M |
| Cash from financing | 29.6M | 19.4M | 22.9M | 35.8M | -1.05M | -629.0K | -1.01M | 46.0K | 23.0M | 907.0K |
| Share buybacks | 22.7M | 7.00K | ||||||||
| Change in cash | -4.36M | -2.71M | -22.0M | 22.8M | -6.33M | 10.3M | 3.36M | -29.4M | 8.77M | -13.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 5, 2026 | Current report | SEC |
| 424B5 · Prospectus | Nov 5, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Nov 3, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Nov 3, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 402 filings. Open Filings
Cap table
Built by 6ix from MediWound Ltd.’s releases · as of Nov 5, 2026
- Common shares
- 12,910,278
- Fully diluted
- 12,910,278
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 12,910,278 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 12,910,278 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Nachum Shamir Other companies: Stereotaxis, Inc. (Director · Since at least Jul 18, 2024); IsoPlexis Corp (Director · Aug 22, 2022 – Mar 21, 2023 · Past); Cactus Acquisition Corp. 1 Limited (Director · Oct 28, 2021 – Oct 28, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Jul 5, 2023 · Past); Cogentix Medical Inc (Director · Nov 3, 2016 – Apr 23, 2018 · Past) | Chairman · Since at least Mar 18, 2026 |
| Stephen T. Wills Other companies: Palatin Technologies, Inc. (Executive VP and CFO/COO · Since at least Dec 6, 2023); Viskase Holdings, Inc. (Director · Jan 7, 2025 – Jan 7, 2025 · Past); Gamida Cell Ltd (Director · Oct 19, 2023 – Jan 31, 2024 · Past) | Director · Since at least Mar 18, 2026 |
| Ofer Gonen Other companies: Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 1, 2022 · Past); Cactus Acquisition Corp. 1 Limited (Chief Executive Officer, Director · Oct 28, 2021 – Oct 28, 2021 · Past) | Chief Executive Officer · Since at least Mar 18, 2026 |
| David Fox Other companies: Archer Aviation Inc. (Director · Oct 27, 2020 – Sep 16, 2021 · Past) | Board Member · Since at least Mar 18, 2026 |
| Samuel Rubinstein Other companies: STRATA Skin Sciences, Inc. (Director · Since at least May 30, 2018) | Director · Since at least Mar 18, 2026 |
| Alexandra Teplitsky | VP Quality Assurance · Since at least Nov 5, 2026 |
| Aya Ben Yaakov | VP Clinical & Regulatory Affairs · Since at least Nov 5, 2026 |
| Barry J. Wolfenson | EVP Strategy & Corporate Development · Since at least Nov 5, 2026 |
| Ety Klinger | Chief Medical Officer · Since at least Mar 18, 2026 |
| Hani Luxenburg | Chief Financial Officer · Since at least Nov 3, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Liron Gal | VP Manufacturing Science & Technology · Since at least Nov 5, 2026 |
| Robert J. Snyder | SVP, Global Medical Affairs · Since at least Apr 28, 2025 |
| Shmuel Rubinstein | Board Member · Since at least Nov 5, 2026 |
| Shmulik Hess | Chief Operating & Commercial Officer · Since at least Nov 3, 2025 |
| Vickie R. Driver | Board Member · Since at least Apr 13, 2026 |
| Yaakov Aya Ben | VP Clinical & Reg. Affairs · Since at least Mar 18, 2026 |
| Yaron Meyer | EVP, General Counsel & Corporate Secretary · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about MediWound Ltd.